Ashwani Verma
Stock Analyst at UBS
(4.31)
# 1,382
Out of 5,104 analysts
217
Total ratings
55%
Success rate
9.9%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Rated: Buy | $52 → $48 | $19.92 | +140.96% | 2 | Nov 3, 2026 | |
| AXSM Axsome Therapeutics | Rated: Buy | $259 → $239 | $139.61 | +71.19% | 13 | Nov 3, 2026 | |
| BHVN Biohaven | Reiterated: Hold | $11 → $15 | $15.61 | -3.91% | 7 | Nov 3, 2026 | |
| INCY Incyte | Reiterated: Hold | $113 → $127 | $117.59 | +8.00% | 14 | Oct 30, 2026 | |
| INSM Insmed | Reiterated: Buy | $172 | $104.44 | +64.69% | 10 | Oct 30, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $337 | $229.74 | +46.69% | 19 | Oct 28, 2026 | |
| LEGN Legend Biotech | Reiterated: Hold | $24 | $21.48 | +11.73% | 12 | Oct 27, 2026 | |
| ALVO Alvotech | Reiterated: Buy | $6 → $8 | $4.54 | +76.21% | 5 | Oct 20, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $115 → $104 | $62.31 | +66.91% | 14 | Oct 15, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $669 → $735 | $396.32 | +85.46% | 2 | Oct 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $49 → $23 | $20.57 | +11.81% | 12 | Oct 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $705 → $725 | $601.32 | +20.57% | 20 | Oct 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 → $26 | $18.92 | +37.42% | 8 | Oct 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $231 → $214 | $164.85 | +29.81% | 20 | Sep 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $66 | $66.40 | -0.60% | 13 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $52 → $13 | $6.81 | +90.90% | 3 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 → $25 | $20.21 | +23.70% | 4 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $40 → $52 | $72.31 | -28.09% | 9 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $95 → $72 | $81.93 | -12.12% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 → $48 | $45.69 | +5.06% | 7 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $220 | $286.00 | -23.08% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,080 | $1,409.38 | -23.37% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $43 | $37.02 | n/a | 5 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 | $29.04 | n/a | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.05 → $1.1 | $0.8056 | n/a | 7 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $119 → $130 | $248.93 | n/a | 4 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.51 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $0.5558 | n/a | 1 | Oct 11, 2022 |
Assembly Biosciences
Nov 3, 2026
Rated: Buy
Price Target: $52 → $48
Current: $19.92
Upside: +140.96%
Axsome Therapeutics
Nov 3, 2026
Rated: Buy
Price Target: $259 → $239
Current: $139.61
Upside: +71.19%
Biohaven
Nov 3, 2026
Reiterated: Hold
Price Target: $11 → $15
Current: $15.61
Upside: -3.91%
Incyte
Oct 30, 2026
Reiterated: Hold
Price Target: $113 → $127
Current: $117.59
Upside: +8.00%
Insmed
Oct 30, 2026
Reiterated: Buy
Price Target: $172
Current: $104.44
Upside: +64.69%
Jazz Pharmaceuticals
Oct 28, 2026
Reiterated: Buy
Price Target: $337
Current: $229.74
Upside: +46.69%
Legend Biotech
Oct 27, 2026
Reiterated: Hold
Price Target: $24
Current: $21.48
Upside: +11.73%
Alvotech
Oct 20, 2026
Reiterated: Buy
Price Target: $6 → $8
Current: $4.54
Upside: +76.21%
Cytokinetics
Oct 15, 2026
Reiterated: Buy
Price Target: $115 → $104
Current: $62.31
Upside: +66.91%
Madrigal Pharmaceuticals
Oct 15, 2026
Reiterated: Buy
Price Target: $669 → $735
Current: $396.32
Upside: +85.46%
Oct 13, 2026
Downgraded: Hold
Price Target: $49 → $23
Current: $20.57
Upside: +11.81%
Oct 13, 2026
Reiterated: Buy
Price Target: $705 → $725
Current: $601.32
Upside: +20.57%
Oct 5, 2026
Reiterated: Buy
Price Target: $23 → $26
Current: $18.92
Upside: +37.42%
Sep 28, 2026
Reiterated: Buy
Price Target: $231 → $214
Current: $164.85
Upside: +29.81%
Sep 8, 2026
Rated: Buy
Price Target: $66
Current: $66.40
Upside: -0.60%
Aug 11, 2026
Downgraded: Hold
Price Target: $52 → $13
Current: $6.81
Upside: +90.90%
Aug 3, 2026
Reiterated: Buy
Price Target: $23 → $25
Current: $20.21
Upside: +23.70%
Jul 2, 2026
Rated: Hold
Price Target: $40 → $52
Current: $72.31
Upside: -28.09%
May 13, 2026
Upgraded: Buy
Price Target: $95 → $72
Current: $81.93
Upside: -12.12%
May 6, 2026
Reiterated: Buy
Price Target: $42 → $48
Current: $45.69
Upside: +5.06%
Nov 7, 2025
Reiterated: Hold
Price Target: $220
Current: $286.00
Upside: -23.08%
Nov 7, 2025
Reiterated: Buy
Price Target: $1,080
Current: $1,409.38
Upside: -23.37%
Oct 14, 2025
Reiterated: Buy
Price Target: $50 → $43
Current: $37.02
Upside: n/a
Jul 29, 2025
Reiterated: Hold
Price Target: $18
Current: $29.04
Upside: n/a
Jul 21, 2025
Reiterated: Hold
Price Target: $1.05 → $1.1
Current: $0.8056
Upside: n/a
Jul 14, 2025
Reiterated: Hold
Price Target: $119 → $130
Current: $248.93
Upside: n/a
Jun 17, 2025
Reiterated: Buy
Price Target: $5
Current: $2.51
Upside: n/a
Oct 11, 2022
Initiated Coverage: Buy
Price Target: $15
Current: $0.5558
Upside: n/a